Yahoo Web Search

  • FirefoxTry Yahoo Search on Firefox »
    1. Biogen’s AD pipeline comprises candidates like aducanumab (an amyloid beta antibody currently in phase III development) as well as a couple of partnered candidates (with Eisai) -- elenbecestat ...

    2. About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies ...

    3. WILEX AG plans rights issue using authorised capital

      EQS Group via Yahoo News23 hours ago

      AG plans to use the expected gross proceeds from the rights issue of EUR 4,999,999.20 million mainly to finance the preclinical development of its proprietary ATAC candidate HDP-101 and to establish ...

    4. The company has initiated phase I study for anti-OX40 agonist antibody – INCAGN1949 – in a phase I/II study in collaboration with Incyte. Also, it plans to initiate studies on anti-PD ...

    5. (ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today presented additional data for eptinezumab (formerly ALD403), which is in Phase 3 ...

    6. (SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced the closing of its ...

    7. Erenumab is a fully human monoclonal antibody specifically designed to target and block the Calcitonin Gene-Related Peptide (CGRP) receptor, believed to have a critical role in mediating ...

    8. MorphoSys to Host Q1 2017 Conference Call on May 3, 2017

      Accesswire via Yahoo News17 hours ago

      About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies ...

    9. X213 is a monoclonal antibody that neutralizes prolactin action. “This proof-of-concept study was an important milestone in demonstrating the potential efficacy of this novel antibody ...

    10. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial ...

    1. 12345208 results